EUVIMEDOpdag EUVIMED
Randomisierte kontrollierte StudieOpen access · CC BY-NC 4.0

Randomized Trial to Assess Worsening Renal Function By Adding Dapagliflozin for Acute Decompensated Heart Failure

Shodai Kawanami, Yasuyuki Egami, Masaru Abe, Mizuki Osuga, Hiroaki Nohara, Kohei Ukita, Akito Kawamura, Koji Yasumoto, Naotaka Okamoto, Yasuharu Matsunaga-Lee, Masamichi Yano, Masami Nishino iD

ESC Heart Failure · 2025

DOI: 10.1002/ehf2.15212 ↗

At a glance

Randomisierte kontrollierte Studie in ESC Heart Failure, 2025. Written by Shodai Kawanami and 11 co-authors. Institution: Division of Cardiology, Osaka Rosai Hospital, Osaka, Japan. Major MEDLINE topics: Heart Failure, Glucosides, Benzhydryl Compounds, Stroke Volume. Cited 6 times so far (Crossref); 26 references. The full text is freely available (open access, CC BY-NC 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Aims

Dapagliflozin (DAPA), a sodium-glucose co-transporter 2 inhibitor, has been shown to reduce cardiovascular mortality among patients with chronic heart failure. We aimed to evaluate the impact on a worsening renal function (WRF) by adding DAPA as compared to standard decongestive therapy with loop diuretics alone. Methods and results We enrolled 114 consecutive acute decompensated heart failure (ADHF) patients with a left ventricular ejection fraction (LVEF) of less than 50%. The patients were prospectively randomized to be assigned either to DAPA group who received DAPA at a dose of 10 mg once daily within 24 h after admission or conventional therapy group (CON group) who received loop diuretics alone. All patients were adjusted by increasing or decreasing the loop diuretic by 10 mg to maintain a 1–2 mL/kg/h urine output. The primary endpoint was the incidence of WRF, which was defined as an increase in the serum creatinine of ≥0.3 mg/dL from baseline. The median age of the patients was 77 [interquartile range (IQR): 64, 85] years, 35% were female and the median LVEF was 33 [IQR: 28, 38] %. There was no significant difference in the incidence of WRF between the two groups (16.1%, n = 9 vs. 12.1%, n = 7, P value = 0.54). The total dose of loop diuretics through day 7 was lower in the DAPA group than CON group (184 ± 79.5 mg vs. 214 ± 66.5 mg, P value = 0.03).

Conclusions

This randomized prospective trial revealed the addition of DAPA within 24 h after admission reduced the diuretic dose without WRF.

Subjects

MeSH terms (MEDLINE)

Heart FailureGlucosidesBenzhydryl CompoundsStroke VolumeGlomerular Filtration RateVentricular Function, LeftHumansFemaleMaleAgedProspective StudiesSodium-Glucose Transporter 2 InhibitorsMiddle AgedAged, 80 and overAcute DiseaseFollow-Up StudiesTreatment OutcomeDisease ProgressionDose-Response Relationship, Drug

Author keywords

acute decompensated heart failuredapagliflozindiureticsworsening renal function

Substances

dapagliflozinGlucosidesBenzhydryl CompoundsSodium-Glucose Transporter 2 Inhibitors

Authors and institutions

  • Division of Cardiology, Osaka Rosai Hospital, Osaka, Japan.

ORCID profiles: Masami Nishino

Cite

APA

Kawanami, S., Egami, Y., Abe, M., Osuga, M., Nohara, H., Ukita, K., Kawamura, A., Yasumoto, K., Okamoto, N., Matsunaga-Lee, Y., Yano, M., & Nishino, M. (2025). Randomized Trial to Assess Worsening Renal Function By Adding Dapagliflozin for Acute Decompensated Heart Failure. ESC Heart Failure. https://doi.org/10.1002/ehf2.15212

Vancouver

Kawanami S, Egami Y, Abe M, Osuga M, Nohara H, Ukita K, et al. Randomized Trial to Assess Worsening Renal Function By Adding Dapagliflozin for Acute Decompensated Heart Failure. ESC Heart Failure. 2025. doi:10.1002/ehf2.15212

BibTeX
@article{Kawanami2025,
  author = {Kawanami, Shodai and Egami, Yasuyuki and Abe, Masaru and Osuga, Mizuki and Nohara, Hiroaki and Ukita, Kohei and Kawamura, Akito and Yasumoto, Koji and Okamoto, Naotaka and Matsunaga-Lee, Yasuharu and Yano, Masamichi and Nishino, Masami},
  title = {Randomized Trial to Assess Worsening Renal Function By Adding Dapagliflozin for Acute Decompensated Heart Failure},
  journal = {ESC Heart Failure},
  year = {2025},
  doi = {10.1002/ehf2.15212}
}
Start for free →